FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 305:1611-1616 December 31, 1981 Number 27 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We measured breathlessness and exercise tolerance in 12 patients with chronic airways obstruction, moderate or severe breathlessness, and low or normal arterial carbon dioxide tension, after the patients received dihydrocodeine, alcohol, caffeine, or placebo (through double-blind administration). Forty-five minutes after ingestion, dihydrocodeine had reduced breathlessness by 20 per cent and increased exercise tolerance by 18 per cent, with a reduction in ventilation and oxygen consumption at submaximal work loads but with no change in spirometric volumes. Oxygen also reduced breathlessness and provided additional benefit to that achieved with dihydrocodeine (at three hours after ingestion) when the two were given together: the reduction of breathlessness was 18 per cent with dihydrocodeine; 22 per cent with oxygen; and 32 per cent with dihydrocodeine plus oxygen. Alcohol increased forced vital capacity by 9 per cent, and exercise tolerance by 7 per cent. Caffeine had no deleterious effect on breathlessness or exercise tolerance, despite increasing ventilation during rest and exercise. We conclude that opiates may be valuable for the treatment of breathlessness in selected patients; further evaluation is needed, particularly of the long-term benefits and safety.

This article has been cited by other articles:

• Rocker, G, Horton, R, Currow, D, Goodridge, D, Young, J, Booth, S (2009). Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 64: 910-915 [Abstract] [Full Text]  
• Mahler, D. A., Murray, J. A., Waterman, L. A., Ward, J., Kraemer, W. J., Zhang, X., Baird, J. C. (2009). Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J 33: 771-777 [Abstract] [Full Text]  
• Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., Zielinski, J. (2007). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 176: 532-555 [Abstract] [Full Text]  
• LeGrand, S. B., Khawam, E. A., Walsh, D., Rivera, N. I. (2003). Opioids, respiratory function, and dyspnea. AM J HOSP PALLIAT CARE 20: 57-61 [Abstract]  
• Jennings, A-L, Davies, A N, Higgins, J P T, Gibbs, J S R, Broadley, K E (2002). A systematic review of the use of opioids in the management of dyspnoea. Thorax 57: 939-944 [Abstract] [Full Text]  
• Aldrich, T. K. (2002). Pink Puffers vs Blue Bloaters in Asthma Too?. Chest 121: 313-315 [Full Text]  
• Mazzocato, C., Sweeney, C., Bruera, E. (2001). Clinical research in palliative care: choice of trial design. Palliat Med 15: 261-264  
• PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., HURD, S. S. (2001). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease . NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am. J. Respir. Crit. Care Med. 163: 1256-1276 [Full Text]  
• Sarhill, N., Walsh, D., Khawam, E., Tropiano, P., Stahley, M. K. (2000). Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. AM J HOSP PALLIAT CARE 17: 389-391 [Abstract]  
• NISHINO, T., IDE, T., SUDO, T., SATO, J. (2000). Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea. Am. J. Respir. Crit. Care Med. 161: 1963-1967 [Abstract] [Full Text]  
• Morrison, R. S., Siu, A. L., Leipzig, R. M., Cassel, C. K., Meier, D. E. (2000). The Hard Task of Improving the Quality of Care at the End of Life. Arch Intern Med 160: 743-747 [Full Text]  
• Chandler, S. (1999). Nebulized opioids to treat dyspnea. AM J HOSP PALLIAT CARE 16: 418-422  
• Zeppetella, G. (1998). The palliation of dyspnea in terminal disease. AM J HOSP PALLIAT CARE 15: 322-330 [Abstract]  
• POOLE, P. J., VEALE, A. G., BLACK, P. N. (1998). The Effect of Sustained-Release Morphine on Breathlessness and Quality of Life in Severe Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 157: 1877-1880 [Abstract] [Full Text]  
• Boyd, K. J, Kelly, M. (1997). Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med 11: 277-281 [Abstract]  
• Shee, C. D (1995). Palliation in chronic respiratory disease. Palliat Med 9: 3-12 [Abstract]  
• Gorman, D. (1991). Review article : Opioid analgesics in the management of pain in patients with cancer: an update. Palliat Med 5: 277-294 [Abstract]  
• de Conno, F., Spoldi, E., Caraceni, A., Ventafridda, V. (1991). Does pharmacological treatment affect the sensation of breathlessness in terminal cancer patients?. Palliat Med 5: 237-243 [Abstract]  
• Tobin, M. J. (1990). Dyspnea. Arch Intern Med 150: 1604-1613 [Abstract]  
• Carrieri, V. K., Janson-Bjerklie, S., Mitchell, P. H. (1986). Strategies Patients Use to Manage the Sensation of Dyspnea. West J Nurs Res 8: 284-305  
• CURATOLO, P. W., ROBERTSON, D. (1983). The Health Consequences of Caffeine. ANN INTERN MED 98: 641-653 [Abstract]